J4 ›› 2009, Vol. 35 ›› Issue (6): 1131-1134.

• 基础研究 • 上一篇    下一篇

D24和SLeX在肺癌组织中的表达及意义

 姜爱英*, 陈志营, 谭平   

  1. 吉林大学中日联谊医院呼吸内科,吉林 长春 130033
  • 收稿日期:2009-06-10 出版日期:2009-11-28 发布日期:2009-11-28
  • 通讯作者: 谭 平 E-mail:tanping _jd@126.com
  • 作者简介:姜爱英(1981-)|女|黑龙江省牡丹江人|医师|医学硕士|主要从事呼吸系统疾病的研究。
  • 基金资助:

    吉林省科技厅科研基金资助课题(200505176)

Expressions and significances of CD24 and SLeX in lung cancer tissues
 JIANG Ai-ying*,CHEN Zhi-ying|TAN Ping

 JIANG Ai-Ying*, CHEN Zhi-Ying, TAN Ping   

  1. Department of Respiratory Medicine,China-Japan Union Hospital,Jilin University,Changchun 130033,China
  • Received:2009-06-10 Online:2009-11-28 Published:2009-11-28

摘要:

目的:探讨CD24和SLeX在肺癌组织中的表达及意义,阐明其与肺癌发生和发展的关系。方法:采用免疫组织化学方法分析CD24和SLeX在70例肺癌组织中的表达。结果:CD24和SLeX在非小细胞肺癌组织中阳性表达率分别为41.3%和63.5%,在小细胞肺癌组织中分别呈无表达和弱表达。CD24和SLeX在腺癌组织中阳性表达率分别为55.9%和76.5%,均明显高于鳞癌(24.1%
和48.3%)(P<0.05)。在肺腺癌、鳞癌组,CD24阳性表达与患者年龄、性别、吸烟指数、肿
瘤分期分级无关联(P>0.05)。而SLeX肺腺癌、鳞癌中,Ⅲ期的阳性表达率(83.3%)高于Ⅰ~Ⅱ期的阳性表达率(55.6%),低分化肺癌(80.8%)高于高、中分化肺癌(51.4%),女性患者(76.7%)高于男性(51.5%),组间比较差异有显著性(P<0.05)。CD24和SLeX呈阳性表达者平均生存时间明显低于阴性表达者(P<0.05)。结论:CD24和SLeX与肺癌的发生、发展关系密切,可以做为判断肺癌患者预后的指标。

关键词: CD24;SLeX;肺肿瘤

Abstract:

Objective
To study the expressions of CD24 and SLeX in lung cancer tissues,and  evaluate the relation ship with  development and progression of lung cancer.Methods Immunohistochemistry was used to detect the expressions of CD24 and SLeX in 70 specimens of lung cancer.Results The positive expression rates of CD24,SLeX in non-small cell lung cancer tissues were 41.3% and 63.5% respectively,There were no expression and weak expression respectively in small cell lung cancer (SCLC) tissues. The positive rates of CD24,SLeX in adenocarcinoma were  55.9% and 76.5%,respectively,which were higher than those in squamous cell carcinoma (24.1%,48.3%)(P<0.05).In lung adenocarcinoma,aquamous cell carcinoma,there was no correlation between CD24-positive patients with age,gender,smoking index,tumor stage and grade(P>0.05).In lung adenocarcinoma and squamous cell carcinoma,the positive expression rate of SLeX  in stage Ⅲ (83.3%) was higher than that in stage Ⅰ-Ⅱ (55.6%),the positive rate in poor differentiated lung cancer(80.8%) was higher than those in  moderate and well differentiate cancer(51.4%),the positive rate in female patients (76.7%) was higher than that in male patients (51.5%)(all P<0.05).The average survival time of the patients with positive expressions of SLeX and CD24 was significantly lower than that of the patients with negative expressions (P<0.05).Conclusion CD24 and SLeX can  play advance roles in the occurrence and development of lung cancer , and they can be used as indicators to judge prognosis in lung cancer.

Key words:  CD24;SLeX;lung neoplasms

中图分类号: 

  •